{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-13T02:54:34.901398+00:00","company":{"ticker":"NVCR","cik":1645113,"company_name":"NovoCure Ltd"},"pagination":{"limit":100,"returned":28,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"shareholder_vote","fact_key":"dd614cc02c2f708ce0cd36896249684791ea733d","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2026-06-05T20:29:35+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of the Company's Amended and Restated 2024 Omnibus Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"10,874,130","subject":null,"votes_abstain":"110,839","votes_against":"41,161,139","votes_for":"41,680,622","votes_withheld":null}]},"claim":"NovoCure Ltd shareholders approved Approval of the Company's Amended and Restated 2024 Omnibus Incentive Plan.","evidence_excerpt":"4. Approval of the Company's Amended and Restated 2024 Omnibus Incentive Plan . The proposal to approve the Company's Amended and Restated 2024 Omnibus Incentive Plan was approved as an ordinary resolution based upon the following votes: For Against Abstain Broker non-votes 41,680,622 41,161,139 110,839 10,874,130","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-26-000050","anchor_url":"https://secwatch.observer/filing/0001645113-26-000050#claim-dd614cc02c2f708ce0cd36896249684791ea733d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f329e680ac40deb7eee061e75a4e7864352cf450","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2026-06-05T20:29:35+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Non-binding advisory vote to approve executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"10,874,130","subject":null,"votes_abstain":"137,556","votes_against":"7,422,876","votes_for":"75,392,168","votes_withheld":null}]},"claim":"NovoCure Ltd shareholders approved Non-binding advisory vote to approve executive compensation.","evidence_excerpt":"3. Approval of a non-binding advisory vote to approve executive compensation . The proposal to approve executive compensation on a non-binding advisory basis was approved as an ordinary resolution based upon the following votes: For Against Abstain Broker non-votes 75,392,168 7,422,876 137,556 10,874,130","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-26-000050","anchor_url":"https://secwatch.observer/filing/0001645113-26-000050#claim-f329e680ac40deb7eee061e75a4e7864352cf450","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6eae985fec45f99444b5e7ccab7a8af468b7acf4","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2026-06-05T20:29:35+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-12-31","outcome":"passed","proposal_text":"Ratification of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"52,565","votes_against":"2,337,255","votes_for":"91,436,910","votes_withheld":null}]},"claim":"NovoCure Ltd shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-12-31 meeting.","evidence_excerpt":"2. Ratification of Independent Registered Public Accounting Firm . The proposal to approve and ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 was approved as an ordinary resolution based upon the following votes: For Against Abstain 91,436,910 2,337,255 52,565","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-26-000050","anchor_url":"https://secwatch.observer/filing/0001645113-26-000050#claim-6eae985fec45f99444b5e7ccab7a8af468b7acf4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7fbde5297e26dfca72cb213c07443b80526990c4","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2026-06-05T20:29:35+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"10,874,130","subject":"Asaf Danziger","votes_abstain":"74,479","votes_against":"1,388,512","votes_for":"81,489,609","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"William Doyle","votes_abstain":"47,401","votes_against":"2,664,190","votes_for":"80,241,009","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"Jeryl Hilleman","votes_abstain":"111,407","votes_against":"1,293,373","votes_for":"81,547,820","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"David Hung","votes_abstain":"144,746","votes_against":"2,039,529","votes_for":"80,768,325","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"Frank Leonard","votes_abstain":"48,852","votes_against":"356,494","votes_for":"82,547,254","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"Kinyip Gabriel Leung","votes_abstain":"126,426","votes_against":"3,370,420","votes_for":"79,455,754","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"Martin Madden","votes_abstain":"130,420","votes_against":"1,461,539","votes_for":"81,360,641","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"Allyson Ocean","votes_abstain":"107,360","votes_against":"1,666,945","votes_for":"81,178,295","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"Timothy Scannell","votes_abstain":"119,768","votes_against":"1,292,301","votes_for":"81,540,531","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"Kristin Stafford","votes_abstain":"96,157","votes_against":"1,272,045","votes_for":"81,584,398","votes_withheld":null},{"broker_non_votes":"10,874,130","subject":"William Vernon","votes_abstain":"119,834","votes_against":"1,483,356","votes_for":"81,349,410","votes_withheld":null}]},"claim":"NovoCure Ltd shareholders approved Election of Directors.","evidence_excerpt":"1. Election of Directors . The eleven nominees for election to the Company’s Board of Directors were elected as directors to hold office until the Company’s 2027 Annual Meeting of Shareholders or until their successors are duly elected and qualified or until their offices are vacated, based upon the following votes: For Against Abstain Broker non-votes Asaf Danziger 81,489,609 1,388,512 74,479 10,874,130 William Doyle 80,241,009 2,664,190 47,401 10,874,130 Jeryl Hilleman 81,547,820 1,293,373 111,407 10,874,130 David Hung 80,768,325 2,039,529 144,746 10,874,130 Frank Leonard 82,547,254 356,494 48,852 10,874,130 Kinyip Gabriel Leung 79,455,754 3,370,420 126,426 10,874,130 Martin Madden 81,360,641 1,461,539 130,420 10,874,130 Allyson Ocean 81,178,295 1,666,945 107,360 10,874,130 Timothy Scannell 81,540,531 1,292,301 119,768 10,874,130 Kristin Stafford 81,584,398 1,272,045 96,157 10,874,130 William Vernon 81,349,410 1,483,356 119,834 10,874,130","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-26-000050","anchor_url":"https://secwatch.observer/filing/0001645113-26-000050#claim-7fbde5297e26dfca72cb213c07443b80526990c4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/0001645113-26-000050-index.htm"},{"fact_type":"earnings_release","fact_key":"8a07118711ce4b4964d928278d6928c0d040cf2a","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2026-04-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2026","report_date":"2026-04-30","result_type":"guidance_update","revenue_text":"Total net revenue: $690 million - $710 million (previous: $675 million - $705 million)"},"claim":"NovoCure Ltd reported full year 2026 results: revenue Total net revenue: $690 million - $710 million (previous: $675 million - $705 million). Guidance raised.","evidence_excerpt":"Novocure’s updated guidance for the full year 2026, as of April 30, 2026, is summarized below: • Total net revenue: $690 million - $710 million (previous: $675 million - $705 million) • Adjusted EBITDA*: $(15) million - $0 million (previous: $(20) million - $0 million)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-26-000043","anchor_url":"https://secwatch.observer/filing/0001645113-26-000043#claim-8a07118711ce4b4964d928278d6928c0d040cf2a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/0001645113-26-000043-index.htm"},{"fact_type":"earnings_release","fact_key":"0bbacc177fa8268e272778da5ab02775ba75c3c0","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2026-04-30T23:59:59+00:00","payload":{"eps_text":"loss per share of $0.62","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the quarter was $71.1 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-04-30","result_type":"reported_results","revenue_text":"Total net revenues for the quarter were $174.1 million"},"claim":"NovoCure Ltd reported first quarter ended March 31, 2026 results: revenue Total net revenues for the quarter were $174.1 million, net income Net loss for the quarter was $71.1 million, EPS loss per share of $0.62.","evidence_excerpt":"Novocure Reports First Quarter 2026 Financial Results Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio ® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 BAAR, Switzerland – April 30, 2026 - Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-26-000043","anchor_url":"https://secwatch.observer/filing/0001645113-26-000043#claim-0bbacc177fa8268e272778da5ab02775ba75c3c0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/0001645113-26-000043-index.htm"},{"fact_type":"executive_change","fact_key":"ffd52bcec8","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-06-04","interim":false,"role":"President, Novocure","role_category":"president","successor_name":null,"successor_named":false},"claim":"Francis Leonard was appointed as President, Novocure at NovoCure Ltd.","evidence_excerpt":"In connection with his appointment of the title \"President, Novocure\" on June 4, 2025 (the \"Award Date\"), Francis Leonard, formerly the Company's Executive Vice President, President Novocure Oncology, was awarded 179,426 Restricted Share Units","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-25-000011","anchor_url":"https://secwatch.observer/filing/0001645113-25-000011#claim-ffd52bcec8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000011/0001645113-25-000011-index.htm"},{"fact_type":"executive_change","fact_key":"98f5b20067","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Christoph Brackmann was appointed as Chief Financial Officer at NovoCure Ltd.","evidence_excerpt":"On October 30, 2024, the Company announced the appointment of Christoph Brackmann, age 51, as the Chief Financial Officer of the Novocure Group, effective January 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-24-000033","anchor_url":"https://secwatch.observer/filing/0001645113-24-000033#claim-98f5b20067","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000033/0001645113-24-000033-index.htm"},{"fact_type":"executive_change","fact_key":"a6e3409779","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-09-03T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-10-01","interim":false,"role":"Senior Advisor","role_category":"other","successor_name":null,"successor_named":false},"claim":"Wilco Groenhuysen resigned as Senior Advisor at NovoCure Ltd.","evidence_excerpt":"On September 3, 2024, the Company also announced that Wilco Groenhuysen, the Company’s Chief Operating Officer, resigned effective October 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-24-000029","anchor_url":"https://secwatch.observer/filing/0001645113-24-000029#claim-a6e3409779","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm"},{"fact_type":"executive_change","fact_key":"4b03bfc757","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-09-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-01-01","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Ashley Cordova was appointed as Chief Executive Officer at NovoCure Ltd.","evidence_excerpt":"On September 3, 2024, the Company announced the appointment of Ashley Cordova, age 45, who is currently serving as the Company’s Chief Financial Officer, as the Chief Executive Officer of the Company and its respective direct and indirect subsidiaries and affiliates (together, the “Novocure Group”), effective January 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-24-000029","anchor_url":"https://secwatch.observer/filing/0001645113-24-000029#claim-4b03bfc757","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm"},{"fact_type":"executive_change","fact_key":"ba8ba5f9eb","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-09-03T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-01-01","interim":false,"role":"Senior Advisor","role_category":"other","successor_name":"Ashley Cordova","successor_named":true},"claim":"Asaf Danziger resigned as Senior Advisor at NovoCure Ltd.","evidence_excerpt":"On September 3, 2024, Asaf Danziger, Chief Executive Officer of NovoCure Limited (the “Company”) resigned from that position effective January 1, 2025 and accepted a new role as Senior Advisor, effective January 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-24-000029","anchor_url":"https://secwatch.observer/filing/0001645113-24-000029#claim-ba8ba5f9eb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000029/0001645113-24-000029-index.htm"},{"fact_type":"earnings_release","fact_key":"c9a6d96e04f7c87e74d2c69739b687379c1c8277","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":"$0.36","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$38.8 million","period_text":"quarter ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":"$138.5 million"},"claim":"NovoCure Ltd reported quarter ended March 31, 2024 results: revenue $138.5 million, net income $38.8 million, EPS $0.36.","evidence_excerpt":"Total net revenues for the quarter were $138.5 million, an increase of 13% compared to the same period in 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-24-000014","anchor_url":"https://secwatch.observer/filing/0001645113-24-000014#claim-c9a6d96e04f7c87e74d2c69739b687379c1c8277","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000014/0001645113-24-000014-index.htm"},{"fact_type":"earnings_release","fact_key":"c5cb831681a170a23c4849dbf56f51528860cffe","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-02-22T23:59:59+00:00","payload":{"eps_text":"loss per share of $0.45","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the quarter was $47.1 million","period_text":"the quarter ended December 31, 2023","report_date":"2024-02-22","result_type":"reported_results","revenue_text":"$133.8 million"},"claim":"NovoCure Ltd reported the quarter ended December 31, 2023 results: revenue $133.8 million, net income Net loss for the quarter was $47.1 million, EPS loss per share of $0.45.","evidence_excerpt":"Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug Administration Enrollment completed in phase 3 TRIDENT trial studying the use of TTFields therapy","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-24-000007","anchor_url":"https://secwatch.observer/filing/0001645113-24-000007#claim-c5cb831681a170a23c4849dbf56f51528860cffe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/0001645113-24-000007-index.htm"},{"fact_type":"earnings_release","fact_key":"7982f36232458c4eb3e97bf6879ed0d3aecaf1dc","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-02-22T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal year ended December 31, 2023","report_date":"2024-02-22","result_type":"reported_results","revenue_text":"$509.3 million"},"claim":"NovoCure Ltd reported the fiscal year ended December 31, 2023 results: revenue $509.3 million.","evidence_excerpt":"Total net revenues for the year were $509.3 million, a decrease of 5% year-over-year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-24-000007","anchor_url":"https://secwatch.observer/filing/0001645113-24-000007#claim-7982f36232458c4eb3e97bf6879ed0d3aecaf1dc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/0001645113-24-000007-index.htm"},{"fact_type":"earnings_release","fact_key":"2a7908f833031f3f796ab259fe705cd2e572a49b","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-01-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2023","report_date":"2024-01-08","result_type":"preliminary_results","revenue_text":"$509.3 million"},"claim":"NovoCure Ltd reported the quarter and year ended December 31, 2023 results: revenue $509.3 million.","evidence_excerpt":"--- EX-99.1 (EX-99.1) ---\n\nNovocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D. appointed as","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-24-000003","anchor_url":"https://secwatch.observer/filing/0001645113-24-000003#claim-2a7908f833031f3f796ab259fe705cd2e572a49b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000003/0001645113-24-000003-index.htm"},{"fact_type":"executive_change","fact_key":"383357b041","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"routine","effective_date":"2024-01-01","interim":false,"role":"Chief Growth Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Pritesh Shah resigned as Chief Growth Officer at NovoCure Ltd.","evidence_excerpt":"Effective January 1, 2024, Pritesh Shah, Chief Growth Officer of the Company, resigned his position as an executive officer of the Company and agreed to become a Senior Advisor to the Chief Executive Officer, a non-executive position.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-24-000002","anchor_url":"https://secwatch.observer/filing/0001645113-24-000002#claim-383357b041","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/0001645113-24-000002-index.htm"},{"fact_type":"executive_change","fact_key":"9d6cfb02c7","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2024-01-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-01","interim":false,"role":"Executive Vice President and President, Novocure Oncology","role_category":"president","successor_name":null,"successor_named":false},"claim":"Frank Leonard was appointed as Executive Vice President and President, Novocure Oncology at NovoCure Ltd.","evidence_excerpt":"Effective January 1, 2024, the Company appointed Frank Leonard, Executive Vice President and President, Novocure Oncology.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-24-000002","anchor_url":"https://secwatch.observer/filing/0001645113-24-000002#claim-9d6cfb02c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/0001645113-24-000002-index.htm"},{"fact_type":"earnings_release","fact_key":"7917f37a13a1912614990194d964767267ae7106","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-10-26T23:59:59+00:00","payload":{"eps_text":"$0.46","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss for the quarter was $49.5 million with loss per share of $0.46","period_text":"the quarter ended September 30, 2023","report_date":"2023-10-26","result_type":"reported_results","revenue_text":"$127.3 million"},"claim":"NovoCure Ltd reported the quarter ended September 30, 2023 results: revenue $127.3 million, net income Net loss for the quarter was $49.5 million with loss per share of $0.46, EPS $0.46.","evidence_excerpt":"Total net revenues for the quarter were $127.3 million, a decrease of 3% compared to the same period in 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-23-000048","anchor_url":"https://secwatch.observer/filing/0001645113-23-000048#claim-7917f37a13a1912614990194d964767267ae7106","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000048/0001645113-23-000048-index.htm"},{"fact_type":"earnings_release","fact_key":"518f93723dc73cdead220243f1cbaa533dd9cbd1","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-07-27T23:59:59+00:00","payload":{"eps_text":"$0.54","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$57.4 million","period_text":"the quarter ended June 30, 2023","report_date":"2023-07-27","result_type":"reported_results","revenue_text":"$126.1 million"},"claim":"NovoCure Ltd reported the quarter ended June 30, 2023 results: revenue $126.1 million, net income $57.4 million, EPS $0.54.","evidence_excerpt":"30, 2023. A copy of the press release is attached as Exhibit 99.1. \n\n--- EX-99.1 (EX-99.1) ---\n\nNovocure Reports Second Quarter 2023 Financial Results Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-23-000045","anchor_url":"https://secwatch.observer/filing/0001645113-23-000045#claim-518f93723dc73cdead220243f1cbaa533dd9cbd1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000045/0001645113-23-000045-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ae9bf36f140507f7f22e8405d4ca34b582a7db82","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-06-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of a non-binding advisory vote to approve executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"11,181,863","subject":null,"votes_abstain":"65,222","votes_against":"25,266,346","votes_for":"52,182,720","votes_withheld":null}]},"claim":"NovoCure Ltd shareholders approved Approval of a non-binding advisory vote to approve executive compensation.","evidence_excerpt":"3. Approval of a non-binding advisory vote to approve executive compensation . The proposal to approve executive compensation on a non-binding advisory basis was approved as an ordinary resolution based upon the following votes: For Against Abstain Broker non-votes 52,182,720 25,266,346 65,222 11,181,863","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-23-000042","anchor_url":"https://secwatch.observer/filing/0001645113-23-000042#claim-ae9bf36f140507f7f22e8405d4ca34b582a7db82","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000042/0001645113-23-000042-index.htm"},{"fact_type":"shareholder_vote","fact_key":"da04b121fc62481eb1d4d884d7de850c6f335584","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-06-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-31","outcome":"passed","proposal_text":"Ratification of Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"78,577","votes_against":"1,174,411","votes_for":"87,443,163","votes_withheld":null}]},"claim":"NovoCure Ltd shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2023-12-31 meeting.","evidence_excerpt":"2. Ratification of Independent Registered Public Accounting Firm . The proposal to approve and ratify the appointment, by the Audit Committee of the Company’s Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the auditor and independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023 was approved as an ordinary resolution based upon the following votes: For Against Abstain 87,443,163 1,174,411 78,577","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-23-000042","anchor_url":"https://secwatch.observer/filing/0001645113-23-000042#claim-da04b121fc62481eb1d4d884d7de850c6f335584","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000042/0001645113-23-000042-index.htm"},{"fact_type":"shareholder_vote","fact_key":"06850be5e425df41908dbd018ad4d33e6e8a9c02","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-06-08T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"11,181,863","subject":"Asaf Danziger","votes_abstain":null,"votes_against":"438,380","votes_for":"77,038,664","votes_withheld":"37,244"},{"broker_non_votes":"11,181,863","subject":"William Doyle","votes_abstain":null,"votes_against":"2,337,997","votes_for":"75,140,162","votes_withheld":"36,129"},{"broker_non_votes":"11,181,863","subject":"Jeryl Hilleman","votes_abstain":null,"votes_against":"961,608","votes_for":"76,517,018","votes_withheld":"35,662"},{"broker_non_votes":"11,181,863","subject":"David Hung","votes_abstain":null,"votes_against":"905,818","votes_for":"76,570,935","votes_withheld":"37,535"},{"broker_non_votes":"11,181,863","subject":"Kinyip Gabriel Leung","votes_abstain":null,"votes_against":"1,506.589","votes_for":"75,970,544","votes_withheld":"37,155"},{"broker_non_votes":"11,181,863","subject":"Martin Madden","votes_abstain":null,"votes_against":"800,747","votes_for":"76,681,847","votes_withheld":"31,694"},{"broker_non_votes":"11,181,863","subject":"Allyson Ocean","votes_abstain":null,"votes_against":"267,279","votes_for":"77,217,389","votes_withheld":"29,620"},{"broker_non_votes":"11,181,863","subject":"Timothy Scannell","votes_abstain":null,"votes_against":"3,439,901","votes_for":"74,042,103","votes_withheld":"32,284"},{"broker_non_votes":"11,181,863","subject":"Kristin Stafford","votes_abstain":null,"votes_against":"180,458","votes_for":"77,300,405","votes_withheld":"33,425"},{"broker_non_votes":"11,181,863","subject":"William Vernon","votes_abstain":null,"votes_against":"2,144,734","votes_for":"75,337,605","votes_withheld":"31,949"}]},"claim":"NovoCure Ltd shareholders approved Election of Directors.","evidence_excerpt":"1. Election of Directors . The ten nominees for election to the Company’s Board of Directors were elected as directors to hold office until the Company’s 2024 Annual Meeting of Shareholders or until their successors are duly elected and qualified or until their offices are vacated, based upon the following votes: For Against Abstain Broker non-votes Asaf Danziger 77,038,664 438,380 37,244 11,181,863 William Doyle 75,140,162 2,337,997 36,129 11,181,863 Jeryl Hilleman 76,517,018 961,608 35,662 11,181,863 David Hung 76,570,935 905,818 37,535 11,181,863 Kinyip Gabriel Leung 75,970,544 1,506.589 37,155 11,181,863 Martin Madden 76,681,847 800,747 31,694 11,181,863 Allyson Ocean 77,217,389 267,279 29,620 11,181,863 Timothy Scannell 74,042,103 3,439,901 32,284 11,181,863 Kristin Stafford 77,300,405 180,458 33,425 11,181,863 William Vernon 75,337,605 2,144,734 31,949 11,181,863","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-23-000042","anchor_url":"https://secwatch.observer/filing/0001645113-23-000042#claim-06850be5e425df41908dbd018ad4d33e6e8a9c02","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000042/0001645113-23-000042-index.htm"},{"fact_type":"earnings_release","fact_key":"bcc4056b484b6f3db4b12af5f972145b3c19bae9","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-05-04T23:59:59+00:00","payload":{"eps_text":"$0.50","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$53.1 million","period_text":"quarter ended March 31, 2023","report_date":"2023-05-04","result_type":"reported_results","revenue_text":"$122.2 million"},"claim":"NovoCure Ltd reported quarter ended March 31, 2023 results: revenue $122.2 million, net income $53.1 million, EPS $0.50.","evidence_excerpt":"Financial updates for the first quarter ended March 31, 2023: • Total net revenues for the quarter were $122.2 million, a decrease of 11% compared to the same period in 2022. ◦ The United States, Germany and Japan contributed $85.2 million, $15.1 million and $8.7 million in quarterly net revenues, respectively, with our other active markets contributing $7.9 million. ◦ Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $5.3 million. • Gross margin for the quarter was 76%. • Research, development and clinical studies expenses for the quarter were $59.7 million, an increase of 41% from the same period in 2022. This primarily reflects increased clinical trial and personnel costs associated with the PANOVA-3 and METIS clinical trials. Total clinical trial expenses can fluctuate quarter-to-quarter dependent upon the amount of clinical research organization services delivered, clinical materials procured and number of trials actively underway. • Sales and marketing exp","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-23-000038","anchor_url":"https://secwatch.observer/filing/0001645113-23-000038#claim-bcc4056b484b6f3db4b12af5f972145b3c19bae9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000038/0001645113-23-000038-index.htm"},{"fact_type":"executive_change","fact_key":"bf31f95835","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-03-29T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-28","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Kristin Stafford was elected as director at NovoCure Ltd.","evidence_excerpt":"On March 28, 2023 , the Board of Directors (the “Board”) of NovoCure Limited (the \"Company\") elected Kristin Stafford as a director of the Company, effective immediately, increasing the size of the Board to ten members.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-23-000032","anchor_url":"https://secwatch.observer/filing/0001645113-23-000032#claim-bf31f95835","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000032/0001645113-23-000032-index.htm"},{"fact_type":"earnings_release","fact_key":"2a85063485b47a965dc12f28aef6b900751213a7","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-02-23T23:59:59+00:00","payload":{"eps_text":"$0.36 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$37.3 million","period_text":"the fourth quarter ended December 31, 2022","report_date":"2023-02-23","result_type":"reported_results","revenue_text":"$128.4 million"},"claim":"NovoCure Ltd reported the fourth quarter ended December 31, 2022 results: revenue $128.4 million, net income $37.3 million, EPS $0.36 per share.","evidence_excerpt":"Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of the pivotal","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-23-000022","anchor_url":"https://secwatch.observer/filing/0001645113-23-000022#claim-2a85063485b47a965dc12f28aef6b900751213a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/0001645113-23-000022-index.htm"},{"fact_type":"earnings_release","fact_key":"df63b2807968a1feda12be2368041410f598ca68","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-02-23T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal year ended December 31, 2022","report_date":"2023-02-23","result_type":"reported_results","revenue_text":"$537.8 million"},"claim":"NovoCure Ltd reported the fiscal year ended December 31, 2022 results: revenue $537.8 million.","evidence_excerpt":"Total net revenues for the year were $537.8 million, an increase of 1% year-over-year.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001645113-23-000022","anchor_url":"https://secwatch.observer/filing/0001645113-23-000022#claim-df63b2807968a1feda12be2368041410f598ca68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/0001645113-23-000022-index.htm"},{"fact_type":"earnings_release","fact_key":"27e5debb218ad2c444907a875963057c4cbb5444","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2023-01-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"for the quarter and year ended December 31, 2022","report_date":"2023-01-09","result_type":"preliminary_results","revenue_text":"$537.8 million"},"claim":"NovoCure Ltd reported for the quarter and year ended December 31, 2022 results: revenue $537.8 million.","evidence_excerpt":"--- EX-99.1 (EX-99.1) ---\n\nNovocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-23-000006","anchor_url":"https://secwatch.observer/filing/0001645113-23-000006#claim-27e5debb218ad2c444907a875963057c4cbb5444","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000006/0001645113-23-000006-index.htm"},{"fact_type":"executive_change","fact_key":"4a05d55bcd","cik":1645113,"ticker":"NVCR","company_name":"NovoCure Ltd","filed_at":"2022-04-13T23:59:59+00:00","payload":{"action":"not stand for reelection","action_category":"departure","departure_tone":"routine","effective_date":"2022-06-08","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sherilyn McCoy departed as Director at NovoCure Ltd.","evidence_excerpt":"On April 11, 2022, Sherilyn McCoy, a Director of NovoCure Limited (the \"Company\") since 2018, notified the Company of her intention not to stand for reelection to the Board of Directors of the Company (the \"Board\") at the Company's 2022 annual general meeting of shareholders (the \"Annual Meeting\"), which is currently scheduled for June 8, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001645113-22-000037","anchor_url":"https://secwatch.observer/filing/0001645113-22-000037#claim-4a05d55bcd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511322000037/0001645113-22-000037-index.htm"}]}